{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:23:55Z","timestamp":1793521435006,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.gastrohep.2012.04.006","type":"journal-article","created":{"date-parts":[[2012,6,29]],"date-time":"2012-06-29T05:16:36Z","timestamp":1340946996000},"page":"512-528","source":"Crossref","is-referenced-by-count":40,"title":["Documento de consenso de la AEEH sobre el tratamiento de la infecci\u00f3n por el virus de la hepatitis B (2012)"],"prefix":"10.1016","volume":"35","author":[{"given":"Mar\u00eda","family":"Buti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garc\u00eda-Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"S\u00e1nchez-Tapias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2012.04.006_bib0005","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1157\/13097663","article-title":"Documento de Consenso de la AEEH sobre el tratamiento de las infecciones por los virus de las hepatitis B y C","volume":"29","author":"Bruguera","year":"2006","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0010","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0020","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0025","doi-asserted-by":"crossref","first-page":"8726","DOI":"10.1016\/j.vaccine.2007.10.027","article-title":"Declining prevalence of hepatitis B virus infection in Catalonia (Spain) 12 years after the introduction of universal vaccination","volume":"25","author":"Salleras","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0030","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0035","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/j.gastro.2004.06.021","article-title":"Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years","volume":"127","author":"Manno","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0040","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1053\/j.gastro.2010.04.048","article-title":"Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study","volume":"139","author":"Liu","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0045","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2008.07.014","article-title":"Statements from the Taormina expert meeting on occult hepatitis B virus infection","volume":"49","author":"Raimondo","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0050","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0060","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gut.2007.128496","article-title":"Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years","volume":"57","author":"Fattovich","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0065","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0070","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0075","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/hep.22878","article-title":"Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time","volume":"49","author":"Tai","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0080","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0085","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","article-title":"Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers","volume":"139","author":"Brunetto","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0090","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0095","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/hep.24364","article-title":"Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review","volume":"53","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0100","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"Moucari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0105","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jhep.2010.12.030","article-title":"Natural history of chronic hepatitis B in Euro-Mediterranean and African countries","volume":"55","author":"Hadziyannis","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0110","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.gastro.2007.11.036","article-title":"Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach","volume":"134","author":"Pawlotsky","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0115","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2009.12.014","article-title":"Is response to antiviral treatment influenced by hepatitis B virus genotype","volume":"52","author":"Raimondi","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0120","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1002\/hep.22976","article-title":"Evaluation of the patient with hepatitis B","volume":"49","author":"Rotman","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0125","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/hep.24013","article-title":"Noninvasive assessment of liver fibrosis","volume":"53","author":"Martinez","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1478-3231.2008.01802.x","article-title":"Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B","volume":"29","author":"Marcellin","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0135","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jhep.2010.07.017","article-title":"Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C","volume":"54","author":"Fraquelli","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0140","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ajg.2010.463","article-title":"Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis B","volume":"106","author":"Fung","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0145","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0150","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"Clinical Practice Guidelines: management of chronic hepatitis B","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0155","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0160","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis","volume":"119","author":"Wong","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0165","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/jhep.2003.50148","article-title":"Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy","volume":"37","author":"Lampertico","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0170","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0168-8278(00)00094-5","article-title":"The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B","volume":"34","author":"Papatheodoridis","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0175","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alpha-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0180","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0185","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0190","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Long-term safety of lamivudine treatment in patients with chronic hepatitis B","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0195","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0200","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0205","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0210","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-147-11-200712040-00183","article-title":"Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial","volume":"147","author":"Chan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0215","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.22658","article-title":"Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir","volume":"49","author":"Leung","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0220","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0225","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","article-title":"Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B","volume":"133","author":"Gish","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0230","first-page":"722A","article-title":"Three years of entecavir (ETV) re-treatment of HBeAg(-) ETV patients who previously discontinued ETV treatment: results from study ETV-901","volume":"48","author":"Shouval","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0235","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0168-8278(09)60022-2","article-title":"Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients","volume":"50","author":"Tenney","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0240","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0245","first-page":"1011A","article-title":"Five years of treatment with tenofovir (TDF) for chronic hepatitis B infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis","volume":"54","author":"Marcellin","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0250","first-page":"480A","article-title":"No detectable resistance to tenofovir disoproxil fumarate(TDF) following up to 240 weeks of treatment in patients with HBeAg+ and HBeAg- chronic hepatitis B virus infection","volume":"54","author":"Marcellin","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0255","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0260","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0265","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0270","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0275","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1016\/S0168-8278(09)60926-0","article-title":"Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a+- lamivudine: results of 5-year post-treatment follow up","volume":"50","author":"Marcellin","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0280","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.23323","article-title":"Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B","volume":"51","author":"Lee","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0285","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350801300106","article-title":"Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication","volume":"13","author":"Lutgehetmann","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0290","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jhep.2009.06.011","article-title":"Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B","volume":"51","author":"Fleischer","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0295","first-page":"1017A","article-title":"A novel combination regimen of peginterferon alfa-2a and entecavir results in sustained post-treatment HBsAg clearance in HBeAg-positive chronic hepatitis B (CHB)","volume":"54","author":"Sheng","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0300","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jhep.2007.12.026","article-title":"Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B","volume":"48","author":"Sung","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0305","first-page":"471A","article-title":"Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide-naive patients with chronic hepatitis B (CHB): the BELOW study","volume":"54","author":"Lok","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0310","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/hep.24406","article-title":"Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response","volume":"54","author":"Zoutendijk","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0315","first-page":"409A","article-title":"Long-term follow-up evaluation of the efficacy and safety of tenofovir disoproxil fumarate (TDF) in a European multicenter (nucleos(t)ide experienced) hepatitis B virus HBV-infected cohort","volume":"50","author":"van Boemmel","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0320","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.23246","article-title":"Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\/nucleotide analogues","volume":"51","author":"van Bommel","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0325","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/jhep.2001.26512","article-title":"Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort","volume":"34","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0330","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/gast.2002.35352","article-title":"Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy","volume":"123","author":"Fontana","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0335","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.24361","article-title":"Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0340","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","article-title":"Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis","volume":"52","author":"Shim","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0345","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.23952","article-title":"Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease","volume":"53","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0350","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.23346","article-title":"Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function","volume":"50","author":"Lange","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0355","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/lt.20402","article-title":"Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence","volume":"11","author":"Marzano","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0360","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/hep.1840130402","article-title":"Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease","volume":"13","author":"Todo","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0365","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1053\/jhep.2002.33681","article-title":"Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease","volume":"35","author":"Steinmuller","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0370","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0168-8278(03)00087-4","article-title":"A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation","volume":"38","author":"Buti","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0375","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1053\/j.gastro.2007.01.005","article-title":"Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation","volume":"132","author":"Gane","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0380","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/lt.22354","article-title":"Hepatitis B immunoglobulin and\/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review","volume":"17","author":"Cholongitas","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0385","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/lt.20981","article-title":"Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results","volume":"13","author":"Schiff","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0390","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1751-2980.2009.00403.x","article-title":"The role of entecavir in preventing hepatitis B recurrence after liver transplantation","volume":"10","author":"Xi","year":"2009","journal-title":"J Dig Dis"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0395","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.transproceed.2010.05.127","article-title":"Efficacy and safety of entecavir and\/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant","volume":"42","author":"Jim\u00e9nez-P\u00e9rez","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0400","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1053\/j.gastro.2011.06.083","article-title":"Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation","volume":"141","author":"Fung","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0405","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0168-8278(01)00039-3","article-title":"Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation","volume":"34","author":"Naoumov","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0410","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/lt.21041","article-title":"Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy","volume":"13","author":"Wong","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0415","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/01.tp.0000277289.23677.0a","article-title":"Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence","volume":"84","author":"Buti","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0420","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22524","article-title":"A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis","volume":"48","author":"Angus","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0425","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/hep.510310233","article-title":"Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation","volume":"31","author":"S\u00e1nchez-Fueyo","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0430","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/hep.1840380407","article-title":"Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease","volume":"38","author":"Bienzle","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0435","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/jhep.2003.50294","article-title":"HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis","volume":"38","author":"Roche","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0440","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/lt.21179","article-title":"Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation","volume":"13","author":"Hussain","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0445","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jhep.2010.12.036","article-title":"Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence","volume":"55","author":"Lenci","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0450","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1086\/377135","article-title":"Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects","volume":"188","author":"Kellerman","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0455","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0460","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/088922203322280874","article-title":"Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications","volume":"19","author":"P\u00e9rez-Olmeda","year":"2003","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0465","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients","volume":"42","author":"Alberti","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0470","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.aids.0000163948.62176.e7","article-title":"Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel","volume":"19","author":"Soriano","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0475","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/egh.11.7","article-title":"Treatment of special populations with chronic hepatitis B infection","volume":"5","author":"Rapti","year":"2011","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0480","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.cld.2010.05.002","article-title":"Management of hepatitis B in special patient populations","volume":"14","author":"Wang","year":"2010","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0485","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-1293.2007.00535.x","article-title":"European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults","volume":"9","author":"Rockstroh","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0490","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1056\/NEJMoa067710","article-title":"The HBV drug entecavir - effects on HIV-1 replication and resistance","volume":"356","author":"McMahon","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0495","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1002\/hep.22965","article-title":"Special populations with hepatitis B virus infection","volume":"49","author":"Peters","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0500","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1002\/hep.22883","article-title":"Hepatitis B and human immunodeficiency virus coinfection","volume":"49","author":"Thio","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0505","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1440-1746.2008.05384.x","article-title":"Hepatitis B virus\/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment","volume":"23","author":"Chu","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0510","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2008.10.049","article-title":"Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses","volume":"136","author":"Liu","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0515","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1016\/j.vaccine.2005.02.033","article-title":"A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis","volume":"23","author":"Liu","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0520","doi-asserted-by":"crossref","unstructured":"Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection--not a vanishing disease in Europe! Hepatology 2007;45:1331-2; author reply 32-3.","DOI":"10.1002\/hep.21590"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0525","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1056\/NEJM199401133300202","article-title":"Treatment of chronic hepatitis D with interferon alfa-2a","volume":"330","author":"Farci","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0530","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0535","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0540","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/TP.0b013e3181806c8c","article-title":"Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients","volume":"86","author":"Kamar","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0545","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1365-2036.2006.03041.x","article-title":"Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis","volume":"24","author":"Fabrizi","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0550","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.21486","article-title":"A randomized controlled trial of lamivudine to treat acute hepatitis B","volume":"45","author":"Kumar","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0555","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jhep.2011.06.007","article-title":"HBV treatment and pregnancy","volume":"55","author":"Petersen","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0560","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2005.05.023","article-title":"The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study","volume":"43","author":"Tse","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0565","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1016\/S0168-8278(11)60738-1","article-title":"Lamivudine in late pregnancy for prevention of HBV transmission: effectiveness and detection of antiviral resistance","volume":"54","author":"Ayres","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0570","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2036.2009.03932.x","article-title":"Clinical course of hepatitis B virus infection during pregnancy","volume":"29","author":"Nguyen","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0575","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1086\/521864","article-title":"Long-term outcome in children with chronic hepatitis B: a 24-year observation period","volume":"45","author":"Iorio","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0580","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jhep.2011.02.032","article-title":"A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection","volume":"55","author":"Han","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0585","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa012452","article-title":"Clinical trial of lamivudine in children with chronic hepatitis B","volume":"346","author":"Jonas","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0590","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.22250","article-title":"Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B","volume":"47","author":"Jonas","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0595","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","article-title":"Management of hepatitis B: summary of a clinical research workshop","volume":"45","author":"Hoofnagle","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0600","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00535-010-0331-4","article-title":"Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy","volume":"46","author":"Kusumoto","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0605","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2036.2010.04570.x","article-title":"Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease","volume":"33","author":"Gisbert","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0610","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"P\u00e9rez-Alv\u00e1rez","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0615","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.21024","article-title":"A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization","volume":"43","author":"Jang","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0620","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2893.2007.00902.x","article-title":"Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis","volume":"15","author":"Katz","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0625","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","article-title":"Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy","volume":"125","author":"Lau","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0630","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1365-2893.2010.01386.x","article-title":"Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy","volume":"18","author":"Li","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gastrohep.2012.04.006_bib0635","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1157\/13095377","article-title":"Prevenci\u00f3n de la hepatitis v\u00edrica","volume":"24","author":"Bruguera","year":"2006","journal-title":"Enferm Infecc Microbiol Clin"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570512001616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570512001616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T22:14:27Z","timestamp":1743632067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570512001616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":127,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0210570512001616"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2012.04.006","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}